Programmable Medicine develops Hydroxyl Dendrimer Therapeutics (HDTs), a clinically validated nanomedicine platform that selectively targets activated inflammatory cells without a targeting ligand minimizing off-target toxicity to normal cells.

Our company offers a competitive compensation package including an annual bonus program, equity and fully paid health care benefits for employees and their families.